Guidelines

Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies

Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy;Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy
University Hospital, Ludwig-Maximilian University, Department of Medicine III, Munich, Germany;Institute for Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilian-University, Munich, Germany
Paul-Ehrlich-Institut, Langen, Germany
Paul-Ehrlich-Institut, Langen, Germany
European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France
European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France
European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France
Trinity College, Dublin, Ireland;European Haemophilia Consortium, Brussels, Belgium
European Haemophilia Consortium, Brussels, Belgium
Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK
Institute for Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilian-University, Munich, Germany
Department of Transfusion Medicine and Haemostasis, Ludwig-Maximilians-University, Munich, Germany
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy
Vol. 105 No. 8 (2020): August, 2020 https://doi.org/10.3324/haematol.2019.242735